Genmab presents full data set for cancer drug

In April, the biotech firm released topline results from a phase II study of its treatment for large B-cell lymphoma, epcoritamab, and Genmab has now revealed the full picture.

Photo: Joost Melis / Genmab / PR

On Saturday, Genmab reported all data from a successful phase II study of drug candidate epcoritamab as a treatment for large B-cell lymphoma (LBCL).

The study’s full outcome was made public at the European Hematology Association (EHA) Presidential Symposium, according to a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs